Business
CHK1 Clinical Trial Application Submissions
CHK1 Clinical Trial Application Submissions.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 5465N Sareum Holdings PLC 01 February 2016 \n\nSAREUM HOLDINGS PLC\n(\"Sareum\" or \"the Company\")\nCHK1 Clinical Trial Application Submissions\nSareum, the specialist cancer drug discovery and development business, is pleased to announce that, further to the Company's announcement of 15 December 2015, the Clinical Trial Applications for Phase I clinical trials of CCT245737, the CHK1 Programme clinical development candidate drug, were submitted to the UK Medicines and Healthcare products Regulatory Agency (MHRA) on 29 January 2016.\nThese Clinical Trial Application submissions trigger a £200,000 success milestone payment from Cancer Research Technology Ltd to Sareum. \nAs reported previously, two clinical trials in cancer patients are planned, one with CCT245737 as a single anti-cancer agent and one in combination with standard-of-care chemotherapy. Once approval is obtained, these trials will be funded in collaboration with co-development partner, the CRT Pioneer Fund. In accordance with the CHK1 co-investment agreement, Sareum satisfied a financial commitment of £797,500 to the funding of this development phase in December 2015.\nSareum's CEO, Dr Tim Mitchell, commented: \"We are delighted to report a further significant step towards these two planned clinical trials with cancer patients and are very pleased to have earned this success milestone.\" \nFor further information:\n\n\n\n\n\nSareum Holdings plc\n\n\n \n\n\n\n\nTim Mitchell\n\n\n 01223 497 700\n\n\n\n\nWH Ireland Limited (Nominated Adviser and Co-Broker)\n\n\n\n\nChris Fielding / Nick Prowting\n\n\n 020 7220 1666\n\n\n\n\nHybridan LLP (Co-Broker)\n\n\n \n\n\n\n\nClaire Noyce / William Lynne\n\n\n 020 3764 2341/2342\n\n\n\n\nThe Communications Portfolio (Media enquiries)\n\n\n \n\n\n\n\nAriane Comstive \[email protected] \n\n\n 07785 922 354\n\n\n\n\nNotes for editors:\nSareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, for licensing to pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.\nSareum operates an outsourced research mo...